Last reviewed · How we verify

Cessation of somatostatin analogues

Australasian Gastro-Intestinal Trials Group · Phase 2 active Small molecule

Cessation of somatostatin analogues is a Small molecule drug developed by Australasian Gastro-Intestinal Trials Group. It is currently in Phase 2 development. Also known as: SSA cessation.

At a glance

Generic nameCessation of somatostatin analogues
Also known asSSA cessation
SponsorAustralasian Gastro-Intestinal Trials Group
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cessation of somatostatin analogues

What is Cessation of somatostatin analogues?

Cessation of somatostatin analogues is a Small molecule drug developed by Australasian Gastro-Intestinal Trials Group.

Who makes Cessation of somatostatin analogues?

Cessation of somatostatin analogues is developed by Australasian Gastro-Intestinal Trials Group (see full Australasian Gastro-Intestinal Trials Group pipeline at /company/australasian-gastro-intestinal-trials-group).

Is Cessation of somatostatin analogues also known as anything else?

Cessation of somatostatin analogues is also known as SSA cessation.

What development phase is Cessation of somatostatin analogues in?

Cessation of somatostatin analogues is in Phase 2.

Related